Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+

• Status: Unknown status
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Acute myeloid leukemia with t(8;21) /AML1-ETO-positive (AE AML) is a heterogeneous disease entailing different prognoses. There were significant differences in the therapeutic effect between different subgroups of AE AML. Therefore, risk stratification-directed therapy is very necessary for AE AML.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital of Southern Medical University
• Collaborator: Zhujiang Hospital
• Treatments: Cytarabine

Criteria

Inclusion Criteria:

• AE AML aged 15-60

• No abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)

• Expected survival time is more than 2 months

Exclusion Criteria:

• Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)

• Patients with any conditions not suitable for the trial (investigators' decision)